National Institute on Aging; Notice of Closed Meeting, 36809 [2017-16521]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 150 / Monday, August 7, 2017 / Notices
The prospective Exclusive Patent
License will be royalty bearing and may
be granted unless within fifteen (15)
days from the date of this published
notice, the National Cancer Institute
receives written evidence and argument
that establishes that the grant of the
license would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated Exclusive Patent
License. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: July 25, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mstockstill on DSK30JT082PROD with NOTICES
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent
License: MicroRNA Therapeutics for
Treating Squamous Cell Carcinomas
AGENCY:
National Institutes of Health,
Notice.
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an Exclusive
Patent License to MiRecule, Inc., located
in Rockville, Maryland, to practice the
inventions embodied in the patent
applications listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
August 22, 2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Michael Shmilovich, Esq.,
Senior Licensing and Patent Manager,
31 Center Drive, Room 4A29, MSC2479,
Bethesda, MD 20892–2479, phone
number 301–435–5019, or shmilovm@
mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement: HHS Ref. No. E–
043–2016/0, including provisional
patent application 62/304,844 filed
March 7, 2016 and International Patent
Application PCT/US2017/021178 filed
March 7, 2017 both entitled
‘‘MicroRNAs And Methods Of Their
Use,’’ and all continuing U.S. and
foreign patents/patent applications for
the technology family, to MiRecule. The
patent rights in these inventions have
been assigned to and/or exclusively
licensed to the Government of the
United States of America.
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Institute on
Aging Special Emphasis Panel; Drugs
Targeting Pathways of Aging.
Date: September 13, 2017.
Time: 3:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, 2W200, 7201 Wisconsin
Avenue, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Anita H. Undale, Ph.D.,
MD, Scientific Review Branch, National
Institute on Aging, Gateway Building, Suite
2W200, 7201 Wisconsin Avenue, Bethesda,
Jkt 241001
[FR Doc. 2017–16521 Filed 8–4–17; 8:45 am]
ACTION:
BILLING CODE 4140–01–P
18:14 Aug 04, 2017
Dated: August 1, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
HHS.
[FR Doc. 2017–16525 Filed 8–4–17; 8:45 am]
VerDate Sep<11>2014
MD 20892, 240–747–7825, anita.undale@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
36809
With respect to persons who have an
obligation to assign their right, title and
interest to the Government of the United
States of America, the patent rights in
these inventions have been assigned to
the Government of the United States of
America.
The prospective Exclusive Patent
License territory may be worldwide for
the following field of use: MicroRNA
therapeutics for squamous cell
carcinomas.
The invention relates to the use of
microRNAs (miRs), miR mimics, miR
mimetics, and a combination thereof as
anti-proliferative cancer therapeutics. In
this case, miRs will be administered in
a form complexed with nanoparticles in
the form of liposomes decorated with
anti-transferrin receptor (TfR) scFv
fragments. Generally, miRs are a highly
conserved class of small RNA molecules
(about 18–24bp) that primarily bind the
3’-UTR region of mRNA molecules and
either block translation or promote
nuclease mediated degradation. The
inventors found that mimics or
mimetics derived from several members
of the miR–30–5p family; and miR–30a–
5p and miR–30e–5p, have potential as
anti-proliferative therapeutics in cancers
including but not limited to squamous
cell carcinomas and currently have a
CRADA with NIDCD exploring their
uses in treating head and neck
squamous cell carcinoma (HNSSC). In
an in vivo proof-of-concept using a
murine xenograft tumor model for
HNSSC, the inventors demonstrated that
intraperitoneal administration of a
nanoliposome formulated with an antitransferrin receptor antibody fragment
and a synthetic miR–30a–5p mimic
strongly delayed tumor growth. Other
anti-cancer miR therapeutic mimics can
be combines with miR–30 including
miR–145–5p, miR–26a–5p, miR–26b–
5p, miR–375–5p, miR–30b–5p, miR–
30d–5p, or miR–338–3p. Modes of
administration can be by intravenous
injection, intraperitoneal injection,
subcutaneous injection, or intratumoral
injection. Therapeutic design employing
miR mimicry focuses on nucleic acid
modifications that exhibit better
cytotoxicity than unmodified miRs or
commercially available mimics. For
example, it is accepted that
modification of the 2’ position of
individual nucleic acids in an
oligonucleotide can improve affinity to
complementary strands and confer
resistance to nucleases and reduce
adverse immunogenic reactions. By way
of another example, bases 1, 6, and 20
of a passenger strand miR can be
mutated to increase the stability of the
resulting duplex; however, these
mutation sites may differ from one
E:\FR\FM\07AUN1.SGM
07AUN1
]]>Agencies
[Federal Register Volume 82, Number 150 (Monday, August 7, 2017)]
[Notices]
[Page 36809]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-16521]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Drugs Targeting Pathways of Aging.
Date: September 13, 2017.
Time: 3:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute on Aging, Gateway Building, 2W200,
7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Anita H. Undale, Ph.D., MD, Scientific Review
Branch, National Institute on Aging, Gateway Building, Suite 2W200,
7201 Wisconsin Avenue, Bethesda, MD 20892, 240-747-7825,
anita.undale@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: August 1, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-16521 Filed 8-4-17; 8:45 am]
BILLING CODE 4140-01-P
